Published in Drug Week, February 24th, 2006
The analysis compares the statistically significant survival benefit demonstrated in favor of orBec in its pivotal phase III clinical trial to the survival results of the earlier successful 60 patient, randomized, double-blinded, placebo-controlled, phase II clinical trial of oral beclomethasone dipropionate for iGVHD.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.